Horizon Therapeutics Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Tim Walbert

Amministratore delegato

US$20.1m

Compenso totale

Percentuale dello stipendio del CEO	6.4%
Mandato del CEO	15.3yrs
Proprietà del CEO	n/a
Durata media del management	2.3yrs
Durata media del Consiglio di amministrazione	9.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Tim Walbert rispetto agli utili di Horizon Therapeutics?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2023	n/a	n/a	US$438m
Mar 31 2023	n/a	n/a	US$372m
Dec 31 2022	US$20m	US$1m	US$521m
Sep 30 2022	n/a	n/a	US$574m
Jun 30 2022	n/a	n/a	US$765m
Mar 31 2022	n/a	n/a	US$862m
Dec 31 2021	US$21m	US$1m	US$534m
Sep 30 2021	n/a	n/a	US$552m
Jun 30 2021	n/a	n/a	US$518m
Mar 31 2021	n/a	n/a	US$280m
Dec 31 2020	US$22m	US$1m	US$390m
Sep 30 2020	n/a	n/a	US$792m
Jun 30 2020	n/a	n/a	US$517m
Mar 31 2020	n/a	n/a	US$592m
Dec 31 2019	US$14m	US$1m	US$573m
Sep 30 2019	n/a	n/a	US$82m
Jun 30 2019	n/a	n/a	US$97m
Mar 31 2019	n/a	n/a	US$77m
Dec 31 2018	US$17m	US$1m	-US$38m
Sep 30 2018	n/a	n/a	-US$178m
Jun 30 2018	n/a	n/a	-US$275m
Mar 31 2018	n/a	n/a	-US$460m
Dec 31 2017	US$2m	US$1m	-US$350m
Sep 30 2017	n/a	n/a	-US$495m
Jun 30 2017	n/a	n/a	-US$437m
Mar 31 2017	n/a	n/a	-US$212m
Dec 31 2016	US$2m	US$950k	-US$166m

Compensazione vs Mercato: La retribuzione totale di Tim ($USD 20.10M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 4.85M ).

Compensazione vs guadagni: La retribuzione di Tim è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Tim Walbert (56 yo)

15.3yrs

Mandato

US$20,103,869

Compensazione

Mr. Timothy P. Walbert, also known as Tim, serves as an Independent Director at Mirum Pharmaceuticals, Inc. from April 05, 2023. He is an Independent Director of Century Therapeutics, Inc. since September...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Timothy Walbert	Chairman	15.3yrs	US$20.10m	Nessun dato
Aaron Cox	Executive VP of Finance & CFO	1.4yrs	US$7.17m	0% € 0
Sean Clayton	Executive VP & General Counsel	1.7yrs	US$10.87m	0% € 0
Andy Pasternak	Executive VP & Chief Strategy Officer	3.9yrs	US$6.75m	0% € 0
Elizabeth Thompson	Executive Vice President of Research & Development	2.6yrs	US$8.48m	0% € 0
Patrick McIlvenny	Senior VP & Chief Accounting Officer	less than a year	Nessun dato	0% € 0
Tina Ventura	Senior VP & Chief Investor Relations Officer	no data	Nessun dato	Nessun dato
Geoffrey Curtis	Executive VP of Corporate Affairs & Chief Communications Officer	7.8yrs	Nessun dato	Nessun dato
Keli Walbert	Executive VP & Chief Marketing Officer	less than a year	Nessun dato	Nessun dato
Jane Gonnerman	Senior VP of Corporate Development & Chief of Staff	2yrs	Nessun dato	Nessun dato
Irina Konstantinovsky	Executive VP	6.1yrs	US$2.31m	Nessun dato
Jeffrey Sherman	Executive VP & Chief Medical Officer	no data	US$5.86m	0% € 0

2.3yrs

Durata media

48yo

Età media

Gestione esperta: Il team dirigenziale di HPR è considerato esperto (durata media dell'incarico 2.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Timothy Walbert	Chairman	15.3yrs	US$20.10m	Nessun dato
Michael Grey	Lead Independent Director	12.1yrs	US$551.24k	0% € 0
William Daniel	Independent Director	9.1yrs	US$522.49k	0% € 0
Jeff Himawan	Independent Director	16.3yrs	US$504.36k	0% € 0
Gino Santini	Independent Director	11.6yrs	US$494.99k	0% € 0
H. Watkins	Independent Director	9.5yrs	US$506.24k	0% € 0
James Shannon	Independent Director	6.2yrs	US$510.61k	0% € 0
Susan Mahony	Independent Director	4.2yrs	US$514.36k	0% € 0
Pascale Witz	Independent Director	6.2yrs	US$496.24k	0% € 0

9.5yrs

Durata media

66yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di HPR sono considerati esperti (durata media dell'incarico 9.5 anni).

Horizon Therapeutics Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Insufficient new directors

Insufficient new directors

Insider recently sold €3.1m worth of stock

Horizon Therapeutics plc Appoints Sean Clayton Executive Vice President

Recent updates

Health Canada Approves Horizon Therapeutics plc 's UPLIZNA® (inebilizumab for injection) for the Treatment of Neuromyelitis Optica Spectrum Disorders

Horizon Therapeutics Public Limited Company Files Form 15

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from S&P Global BMI Index

Horizon Therapeutics Public Limited Company Announces New Analysis of Adhering to Uninterrupted Full Course of Treatment with Tepezza to Support Thyroid Eye Disease Patient Outcomes

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart for Severe Alopecia Areata

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Horizon Therapeutics Public Limited Company to Report Q2, 2023 Results on Aug 08, 2023

Horizon Therapeutics plc Announces New Analysis of MRI Findings Shows UPLIZNA®? (inebilizumab-cdon) Reduced the Formation of Subclinical Spinal Cord Lesions in People with Neuromyelitis Optica Spectrum Disorder

Horizon Therapeutics plc Announces Tepezza® (Teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease

Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (Optic-J) in Japan

Horizon Therapeutics plc Announces Additional Data from Phase 4 TEPEZZA® (teprotumumab-trbw) Clinical Trial Presented at the Endocrine Society Annual Meeting Reinforces Efficacy in People with Thyroid Eye Disease (TED) Regardless of Disease Activity or Duration

Horizon Therapeutics plc Announces the Publication of New Analysis from the N-MOmentum Clinical Trial of UPLIZNA Demonstrating the Utility of A Robust Assay Process

Horizon Therapeutics plc Announces Data from the Teprotumumab Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease

Horizon Therapeutics plc Announces the Publication of New Data from the Phase 3 N-MOmentum Pivotal Trial of UPLIZNA

Horizon Therapeutics plc Announces Presentations At the 2023 Eular European Congress of Rheumatology Highlight New Results from Phase 2 Trial Evaluating Dazodalibep in Sjögren’S Syndrome

Horizon Therapeutics Public Limited Company to Report Q4, 2022 Results on Mar 01, 2023

Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus

Amgen Inc. (NasdaqGS:AMGN) entered into a transaction agreement to acquire Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP) for $27.1 billion.

Amgen Reportedly in Advanced Talks to Buy Horizon Therapeutics

Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout

Investor sentiment improved over the past week

Insufficient new directors

Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (Optic-J) in Japan Evaluating Tepezza® for the Treatment of Active Thyroid Eye Disease

Horizon Therapeutics plc Announces That Month 12 Data from the Mirror Randomized Controlled Trial of Krystexxa® (Pegloticase) Injection

Investor sentiment improved over the past week

Horizon Therapeutics plc Announces That Month 12 Data from the Mirror Randomized Controlled Trial of Krystexxa® (Pegloticase) Injection

Horizon Therapeutics Public Limited Company Announces Data Support the Use of KRYSTEXXA (Pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People with Mild-To-Moderate Chronic Kidney Disease

Third quarter 2022 earnings released: EPS: US$0.59 (vs US$1.44 in 3Q 2021)

Horizon Therapeutics Public Limited Company Revises Earnings Guidance for the Full Year 2022

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis

Horizon Therapeutics plc Announces New Data from Two Analyses of the Uplizna Phase 3 Pivotal Trial Presented At the 38(Th) Congress of the European Committee for Treatment and Research in Multiple Sclerosis (Ectrims 2022), Oct. 26-28 in Amsterdam

Horizon Therapeutics Public Limited Company to Report Q3, 2022 Results on Nov 02, 2022

Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA® (Teprotumumab-Trbw) in Adults with Chronic/Low Clinical Activity Score (Cas) Thyroid Eye Disease (Ted)

Horizon Therapeutics plc Announces Data from the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection with Methotrexate Published in Arthritis & Rheumatology

Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint

Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP) announces an Equity Buyback for $500 million worth of its shares.

Second quarter 2022 earnings released: EPS: US$0.27 (vs US$0.70 in 2Q 2021)

Horizon Therapeutics Public Limited Company Reports Impairment of Goodwill for the Second Quarter Ended June 30, 2022

FDA Approves KRYSTEXXA® (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy

Horizon Therapeutics Public Limited Company to Report Q2, 2022 Results on Aug 03, 2022

Horizon Therapeutics Public Limited Company Announces New Analysis Finds UPLIZNA (inebilizumab) Effective Among European Populations with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Horizon Therapeutics plc Submits Regulatory Filing for Uplizna® (Inebilizumab) in Brazil

Horizon Therapeutics Public Limited Company Announces Results of A New Analysis Examining Rates of Hyperglycemia Among Patients Treated with TEPEZZA for TED Compare to Placebo in the Phase 2 and OPTIC Phase 3 Clinical Trials

Horizon Therapeutics plc Announces Analysis from the Phase 3 N-Momentum Study Demonstrates the Effectiveness of Uplizna(R) (Inebilizumab-Cdon) Among Neuromyelitis Optica Spectrum Disorder Patients with Genetic Variations

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab (Hzn-7734) for the Treatment of Alopecia Areata

First quarter 2022 earnings released: EPS: US$0.89 (vs US$0.55 loss in 1Q 2021)

Horizon Therapeutics Public Limited Company Provides Earnings Guidance for the Full Year 2022

Horizon Therapeutics plc Receives European Commission Approval of Uplizna (Inebilizumab) for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder

Insufficient new directors

Horizon Therapeutics Public Limited Company to Report Q1, 2022 Results on May 04, 2022

Horizon Therapeutics plc Announces Presentation of A Post-Hoc Analysis from the N-Momentum Phase 3 Pivotal Trial of UPLIZNA

Insider recently sold €3.1m worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Horizon Therapeutics plc Provides Earnings Guidance for the Full Year 2022

Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED)

Horizon Therapeutics plc Appoints Sean Clayton Executive Vice President

Horizon Therapeutics Public Limited Company Announces Results from a New Post-Marketing Safety Analysis of Hearing Events Associated with Tepezza for the Treatment of Thyroid Eye Disease

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media